https://www.selleckchem.com/products/amg510.html
BACKGROUND The serum marker CA 125 is still the most widely used biomarker for ovarian cancer (OC) diagnosis in gynecological and oncological setting, but its predictive role in early-stage OC is still debated. The aim of this study was to explore the value of CA 125 in distinguishing between early-stage OC and borderline ovarian tumor (BOT) and to evaluate the accuracy of CA 125 in the detection of early stage OC. METHODS A retrospective cohort study was performed at the University Hospital of Bologna (Italy) on 1296 consecutive women s
Like
Comment
Share
